Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1425-31. doi: 10.1007/s00259-015-3264-6. Epub 2015 Dec 3.

Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases.

Author information

1
Department of Radiology, Uppsala University Hospital, 751 85, Uppsala, Sweden. Charlotte.Ebeling_Barbier@radiol.uu.se.
2
Department of Surgical Sciences, Section of Nuclear Medicine and PET, Uppsala University Hospital, Uppsala, Sweden.
3
Department of Radiology, Uppsala University Hospital, 751 85, Uppsala, Sweden.
4
Department of Medical Sciences, Division of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.

Abstract

PURPOSE:

To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in patients with unresectable liver metastases from neuroendocrine tumours (NETLMs).

METHODS:

This retrospective study included 40 patients with progressive NETLMs (22 women, 18 men, mean age 61.6 years) who underwent SIRT with (90)Y-labelled resin microspheres. Tumour response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) on CT or MR images. Medical records were reviewed.

RESULTS:

In the 40 patients, 54 evaluable SIRT procedures were performed, 33 to the right liver lobe (mean activity 1.31 GBq), 13 to the left lobe (mean activity 0.85 GBq), and 8 to both lobes (mean activity 1.61 GBq). Late follow-up imaging (mean 20 months) was performed after 44 of the treatments. Objective tumour response and disease control rates were 54 % (29 of 54 treatments) and 94 % (51 treatments), respectively, at the early follow-up examination (mean 3 months) and 34 % (15 treatments) and 57 % (25 treatments), respectively at the late follow-up examination. Mean overall survival from the first SIRT was 34,8 months and survival rates at 1, 2, 3 and 5 years were 76 %, 59 %, 52 % and 35 % respectively. Adverse effects were generally mild and easily manageable, except in one patient who died from radiation-induced liver failure. Of the 45 patients, 18 (45 %) had received peptide receptor radionuclide therapy (PRRT) prior to SIRT.

CONCLUSION:

SIRT with (90)Y-labelled resin microspheres is a safe and effective treatment for patients with progressive NETLM, and also for those who have received prior PRRT.

KEYWORDS:

Neuroendocrine liver metastases; Selective internal radiation therapy; Transarterial; Yttrium

PMID:
26631239
DOI:
10.1007/s00259-015-3264-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center